Alnylam Pharmaceuticals
ALNY
169 hedge funds and large institutions have $3.57B invested in Alnylam Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 60 increasing their positions, 66 reducing their positions, and 27 closing their positions.
19% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 27
9% more capital invested
Capital invested by funds: $3.28B → $3.57B (+$296M)
3% more funds holding
Funds holding: 164 → 169 (+5)
9% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 66
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
35% less call options, than puts
Call options by funds: $7.17M | Put options by funds: $11.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$363M |
| 2 |
AWG
Alpha Wave Global
New York
|
+$59.7M |
| 3 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$35.5M |
| 4 |
Morgan Stanley
New York
|
+$32.9M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$21.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$63.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$25.2M |
| 3 |
DM
Deerfield Management
New York
|
-$24.5M |
| 4 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$22.4M |
| 5 |
BG
BlackRock Group
London,
United Kingdom
|
-$19.2M |
ALNY Hedge Fund Activity: Q4 2013 in Review
169 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2013, worth a combined $3.57B — up 9% from $3.28B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ALNY positions and 27 closed out — a net gain of 5 holders — while 60 added to existing stakes and 66 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $363M. The largest seller was BlackRock Advisors, cutting an estimated $63.2M.
- 169 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2013, up from 164 in Q3 2013.
- Funds reported $3.57B of Alnylam Pharmaceuticals stock for Q4 2013, up 9% quarter-over-quarter.
- 32 funds opened new Alnylam Pharmaceuticals positions in Q4 2013 and 27 closed out, a net change of +5 holders.
- The largest Alnylam Pharmaceuticals buyer in Q4 2013 was Wellington Management Group, an estimated $363M added.
- The largest Alnylam Pharmaceuticals seller in Q4 2013 was BlackRock Advisors, an estimated $63.2M sold.
Based on aggregated 13F filings for Q4 2013.